Stocks and Investing
Stocks and Investing
Tue, May 17, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jason Gerberry Upgraded (TEVA) to Hold and Held Target at $9 on, May 17th, 2022
Jason Gerberry of B of A Securities, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Hold and Held Target at $9 on, May 17th, 2022.
Jason has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Nathan Rich of "Goldman Sachs" Maintained at Hold with Decreased Target to $9 on, Thursday, May 12th, 2022
- Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, January 27th, 2022
These are the ratings of the 2 analyists that currently disagree with Jason
- David Amsellem of "Piper Sandler" Downgraded from Hold to Sell and Decreased Target to $7 on, Wednesday, May 4th, 2022
- Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
Contributing Sources